Aegirbio eyes new acquisitions following Thyrolytics deal
September 24, 2020
AegirBio, a diagnostic company that offers tests to monitor and optimize the dosage of biological drugs, has announced the acquisition of Thyrolytics. AegirBio, which IPOed on Nasdaq First North Growth in June, is now pursuing a growth strategy that involves acquisitions of complementary companies according to CEO Martin Linde.
ⓘ This story was originally featured in our daily M&A Insights newsletter.
